Zenas BioPharma, Inc. (NASDAQ:ZBIO) Receives Consensus Rating of “Hold” from Analysts

Zenas BioPharma, Inc. (NASDAQ:ZBIO) has been assigned an average rating of “Hold” from the nine analysts that are currently covering the company, MarketBeat.com reports. Two equities research analysts have rated the stock with a sell recommendation, one has given a hold recommendation and six have issued a buy recommendation on the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $44.1429.

Several analysts have recently commented on ZBIO shares. Citigroup decreased their target price on Zenas BioPharma from $43.00 to $41.00 and set a “buy” rating on the stock in a report on Tuesday, March 17th. HC Wainwright reiterated a “buy” rating and set a $44.00 price target on shares of Zenas BioPharma in a research report on Tuesday, March 17th. Morgan Stanley increased their price objective on shares of Zenas BioPharma from $19.00 to $21.00 and gave the stock an “equal weight” rating in a report on Tuesday, March 17th. Guggenheim raised their price objective on shares of Zenas BioPharma from $45.00 to $55.00 and gave the company a “buy” rating in a research report on Monday, March 16th. Finally, Jefferies Financial Group reaffirmed a “buy” rating and issued a $48.00 target price on shares of Zenas BioPharma in a research note on Tuesday, January 6th.

Insider Activity at Zenas BioPharma

In other news, CEO Leon O. Moulder, Jr. acquired 57,000 shares of Zenas BioPharma stock in a transaction on Monday, February 2nd. The shares were purchased at an average price of $17.96 per share, with a total value of $1,023,720.00. Following the acquisition, the chief executive officer owned 423,155 shares in the company, valued at $7,599,863.80. This represents a 15.57% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Hongbo Lu acquired 25,985 shares of the firm’s stock in a transaction on Wednesday, February 11th. The stock was purchased at an average price of $22.50 per share, for a total transaction of $584,662.50. Following the completion of the transaction, the director directly owned 347,968 shares in the company, valued at approximately $7,829,280. The trade was a 8.07% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders purchased a total of 202,845 shares of company stock valued at $3,747,185 over the last quarter. Corporate insiders own 22.00% of the company’s stock.

Hedge Funds Weigh In On Zenas BioPharma

Large investors have recently made changes to their positions in the company. SR One Capital Management LP boosted its holdings in Zenas BioPharma by 2.6% in the fourth quarter. SR One Capital Management LP now owns 5,037,854 shares of the company’s stock valued at $182,924,000 after acquiring an additional 126,315 shares during the last quarter. NEA Management Company LLC raised its holdings in Zenas BioPharma by 28.9% during the 4th quarter. NEA Management Company LLC now owns 3,523,219 shares of the company’s stock worth $127,928,000 after purchasing an additional 789,500 shares during the last quarter. Federated Hermes Inc. lifted its position in Zenas BioPharma by 45.9% during the 4th quarter. Federated Hermes Inc. now owns 2,715,578 shares of the company’s stock valued at $98,603,000 after purchasing an additional 853,740 shares during the period. Vanguard Group Inc. lifted its position in Zenas BioPharma by 25.0% during the 4th quarter. Vanguard Group Inc. now owns 1,453,065 shares of the company’s stock valued at $52,761,000 after purchasing an additional 290,307 shares during the period. Finally, Polar Capital Holdings Plc bought a new position in shares of Zenas BioPharma in the 4th quarter valued at about $38,402,000.

Zenas BioPharma Stock Up 5.4%

NASDAQ ZBIO opened at $22.19 on Thursday. The firm has a market cap of $1.27 billion, a PE ratio of -2.84 and a beta of -1.94. Zenas BioPharma has a one year low of $6.11 and a one year high of $44.60. The stock’s 50 day simple moving average is $23.17 and its 200 day simple moving average is $27.30. The company has a debt-to-equity ratio of 0.32, a current ratio of 5.61 and a quick ratio of 5.61.

Zenas BioPharma (NASDAQ:ZBIO) last released its quarterly earnings results on Monday, March 16th. The company reported ($4.54) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.22) by ($3.32).

About Zenas BioPharma

Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.